Bourlière, Marc <br/><br/>
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.  [electronic resource] 

 -  The lancet. Gastroenterology & hepatology  08 2018 
 - 559-565 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2468-1253 
<br/><br/><label>Standard No.: </label>10.1016/S2468-1253(18)30118-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aminoisobutyric Acids<br/>Antiviral Agents--adverse effects<br/>Carbamates--adverse effects<br/>Cyclopropanes<br/>Drug Combinations<br/>Female<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--drug therapy<br/>Heterocyclic Compounds, 4 or More Rings--adverse effects<br/>Humans<br/>Lactams, Macrocyclic<br/>Leucine--analogs & derivatives<br/>Macrocyclic Compounds--adverse effects<br/>Male<br/>Middle Aged<br/>Proline--analogs & derivatives<br/>Quinoxalines<br/>RNA, Viral--blood<br/>Sofosbuvir--adverse effects<br/>Sulfonamides--adverse effects<br/>Treatment Failure<br/>Viral Nonstructural Proteins--antagonists & inhibitors